Sakar Healthcare Ltd, an Ahmedabad-based pharmaceutical company, reported a remarkable 91% increase in net profit for the January-March quarter of 2025-26, reaching ₹11.02 crore compared to ₹5.76 crore in the same quarter last year. The company's revenue from operations also saw a substantial rise of 42%, totaling ₹71.09 crore against ₹50.24 crore in the previous year. For the entire fiscal year ending March 31, 2026, Sakar's net profit surged 74% to ₹30.48 crore, up from ₹17.50 crore in FY25, while total revenue climbed 42% to ₹251.73 crore from ₹177.58 crore. The Managing Director, Sanjay Shah, emphasized the growing importance of oncology in Sakar's overall growth strategy, noting that the company has completed over 60 business contracts involving oncology products, which are expected to play a crucial role in shaping future growth.